Insilico Medicine is a bioinformatics company utilizes advances in genomics, big data analysis, and deep learning for in silico drug discovery and drug repurposing for age-related diseases. The company pursues internal drug discovery programs in cancer, Parkinson's disease, Alzheimer's disease, Sarcopenia, and Geroprotector discovery. It uses specialized tools such as iPANDA (for signaling pathway activation analysis), PharmaAI (drug discovery engine) and DeepPharma (the predictor of phase I/II clinical trials). It is also working with its collaborators to investigate ALS disease and its new treatments.